Name: Yi Pan

Title: Deputy Director of the Department of Radiation Oncology

Specialties: Radiation oncology

Clinical Interests: chemoradiotherapy and immunotherapy for lung cancer, particularly on treatment-related toxicity and predictive biomarker.

Education:

2013-12. 2014 PhD Student of Oncology University of Southern Denmark

2012-12. 2015 MD of Oncology Southern Medical University

2003-6. 2006 Master of Oncology Cancer Center of Sun Yat-sen University

1994 -6. 1999 MBBS Sun Yat-sen University of Medical Sciences (SUMS)

Professional memberships:

Fellow of Lung Cancer Committee of China Anti-Cancer Association

Vice Chair of Cancer Committee of Guangdong Medical Association

Fellow of Standing Committee of Radiation Oncology, Guangdong Medical Association

Fellow of Standing Committee of Radiotherapy, Guangdong Medical Doctor Association

Publications:

1. Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy. Radiother Oncol. 2016,118(3): 465-70
2. Planed PET-CT scan in follow-up early detected disease progression in patients with locally advanced NSCLC receiving curative chemo radiotherapy. Medicine, 2015,94(43):e1863
3. The effect of lentivirus-mediated small interfering RNA targeting DNA-PKcs on epidermal growth factor receptor translocation and sensitivity to C225 in lung cancer cell line. Chinese Journal of Experimental Surgery, 2014, 21(8): 1626-28
4. Treatment of Gemcitabine combined with nedaplatin and paclitaxel for patients with metastatic cisplatin-resistant nasopharyngeal carcinoma. Cancer Research And Clinic, 2010,22(8):519-20
5. siRNA in silencing the expression of DNA-dependent protein kinase and tis effect on radiosensitivity of lung adenocacinoma cells. Chinese Journal of radiation Oncology, 2010,19(1):66-9
6. Correlation of DNA-dependent protein kinase catalytic subunit expression to radiosensitivity of non-small cell lung cancer cell lines. Ai Zheng. 2009 Jul;28(7):714-7
7. Nuclear and cytoplasmic expressions of survivin in glioma and their prognostic value. Zhonghua Yi Xue Za Zhi. 2007 Jan 30;87(5):325-9
8. Nuclear Expression of Survivin in Glioma and Its Correlation to Prognosis. Aizheng, 2006,25(5): 635-9.
9. Nuclear and cytoplasmic expression of survivin in glioma and their correlation to p53, Ki67 and MVD. Chinese Journal of Cancer Prevention And Treatment, 2006, 13(23)s:24-7
10. Changes of Visual Field and Visual Evoked Potential in Nasopharyngeal Carcinoma Patients after Radiotherapy. Aizheng, 2005,24(6): 722-6.